908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook

Q1 2022 revenue increases 50% over prior year with Desktop revenue in BioPharma growing 68%

BOSTON–(BUSINESS WIRE)–908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022.

“We had a strong start to the year with revenue growing 50% over the prior year period. We made tangible progress against our goals as we continued to enable our customers with rapid chemical and biochemical analysis when and where they need it,” said Kevin J. Knopp, CEO and Co-founder. “From global biopharma sites to prominent local events in our communities, like the Boston Marathon, our devices are being used to provide actionable insights.”

Recent Highlights

  • Revenue of $8.3 million for the first quarter of 2022, representing 50% increase over the prior year period
  • Expanded installed base to 2,018 devices with 83 devices placed during the first quarter
  • Released updates to our MX908 handheld device, including additional drug targets, Bluetooth capability for iOS devices and technical interface spec for robots, drones, and other third-party systems
  • Partnered with UK-based CPI biologics center on cell culture media optimization for bioprocessing applications

First Quarter 2022 Financial Results

Revenue was $8.3 million for the three months ended March 31, 2022, a 50% increase over the prior year period. This increase was primarily driven by product revenue from an increase in both handheld and desktop devices. Desktop revenue grew 68% year over year because of both increased device sales and increased recurring revenue.

The installed base grew to 2,018 placements with 83 devices placed in Q1 2022.

Gross profit was $4.1 million for the first quarter of 2022, compared to $2.9 million for the corresponding prior year period. Gross margin was 50%, as compared to 52% for the corresponding prior year period. The decrease in gross margin was expected based upon the investments in personnel and expenses in calendar year 2021 and the first quarter of 2022, offset in part by the increase in device sales and the volume leverage.

Operating expenses were $13.7 million for the first quarter of 2022, compared to $8.7 million for the corresponding prior year period. This increase was driven by headcount expansion across our business, an increase in stock-based compensation and an increase in marketing activities and travel expenses.

Net loss was $9.4 million for the first quarter of 2022, compared to a net loss of $6.1 million for the corresponding prior year period. Net loss per share was $0.30 for the first quarter of 2022, compared to a net loss per share of $0.22 for the corresponding prior year period.

Cash and cash equivalents were $223 million as of March 31, 2021. In addition, the Company has approximately $15 million of debt outstanding.

2022 Guidance

908 Devices continues to expect full year 2022 revenue to be in the range of $52 million to $55 million, representing 23% to 30% growth over full year 2021.

Webcast Information

908 Devices will host a conference call to discuss the first quarter 2022 financial results before market open on Tuesday, May 10, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

908 DEVICES INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

 

2022

 

2021

Revenue:

 

 

 

 

 

 

Product and service revenue

 

$

8,029

 

 

$

5,357

 

License and contract revenue

 

 

277

 

 

 

186

 

Total revenue

 

 

8,306

 

 

 

5,543

 

Cost of revenue:

 

 

 

 

 

 

Product and service cost of revenue

 

 

4,041

 

 

 

2,560

 

License and contract cost of revenue

 

 

136

 

 

 

75

 

Total cost of revenue

 

 

4,177

 

 

 

2,635

 

Gross profit

 

 

4,129

 

 

 

2,908

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

3,905

 

 

 

2,965

 

Selling, general and administrative

 

 

9,745

 

 

 

5,753

 

Total operating expenses

 

 

13,650

 

 

 

8,718

 

Loss from operations

 

 

(9,521

)

 

 

(5,810

)

Other income (expense):

 

 

 

 

 

 

Interest expense

 

 

(20

)

 

 

(376

)

Other income, net

 

 

126

 

 

 

91

 

Total other income (expense), net

 

 

106

 

 

 

(285

)

Net loss and comprehensive loss

 

$

(9,415

)

 

$

(6,095

)

Net loss per share attributable to common stockholders

 

$

(0.30

)

 

$

(0.22

)

Weighted average common shares outstanding

 

 

31,210,567

 

 

 

27,290,364

 

908 DEVICES INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

March 31,

 

December 31,

 

 

2022

 

2021

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

223,120

 

$

224,073

Accounts receivable, net

 

 

6,323

 

 

16,375

Inventory

 

 

9,632

 

 

7,918

Prepaid expenses and other current assets

 

 

3,908

 

 

4,527

Total current assets

 

 

242,983

 

 

252,893

Operating lease, right-of-use assets

 

 

4,886

 

 

5,182

Property and equipment, net

 

 

2,177

 

 

1,603

Other long-term assets

 

 

1,180

 

 

1,228

Total assets

 

$

251,226

 

$

260,906

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,162

 

$

1,371

Accrued expenses

 

 

4,350

 

 

6,961

Deferred revenue

 

 

5,779

 

 

5,160

Operating lease liabilities

 

 

1,373

 

 

1,344

Total current liabilities

 

 

13,664

 

 

14,836

Long-term debt, net of discount and current portion

 

 

15,000

 

 

15,000

Operating lease liabilities, net of current portion

 

 

4,156

 

 

4,508

Deferred revenue, net of current portion

 

 

11,604

 

 

11,958

Total liabilities

 

 

44,424

 

 

46,302

Total stockholders’ equity

 

 

206,802

 

 

214,604

Total liabilities and stockholders’ equity

 

$

251,226

 

$

260,906

Source: 908 Devices Inc.

Contacts

Investor Contact:
Carrie Mendivil

[email protected]

error: Content is protected !!